Using blaZ PCR as the "gold standard," the sensitivities of CLSI penicillin zone edge and nitrocefin-based tests for ␤-lactamase production in Staphylococcus aureus were 64.5% and 35.5%, respectively, with specificity of 99.8% for both methods. In 2013, 13.5% of 3,083 S. aureus isolates from 31 U.S. centers were penicillin susceptible. P enicillinase-producing strains of Staphylococcus aureus emerged in the 1940s and by the 1970s represented 70 to 85% of the S. aureus population (1). Four types of blaZ genes (A to D) have been associated with penicillinase production in S. aureus (2). A study conducted in Germany demonstrated the sensitivity of nitrocefinbased testing was unacceptably low (36%) for penicillinase detection compared to blaZ PCR (3). Since 2012, the Clinical and Laboratory Standards Institute (CLSI) has recommended the penicillin zone edge test (4) to screen S. aureus isolates with a susceptible penicillin MIC (Յ0.12 g/ml) or disk zone (Ն29 mm) for ␤-lactamase production (5).
. The blaZ type was also determined for a subset of penicillinresistant isolates (n ϭ 51). The penicillin zone edge test was performed on Mueller-Hinton agar using a 10-U penicillin disk following CLSI guidelines (5) . After 16 to 18 h of incubation in ambient air, a sharp zone edge was interpreted as positive and a fuzzy zone as negative for ␤-lactamase production. Nitrocefinbased testing was performed on induced growth taken from the zone margin surrounding a 10-U penicillin disk.
As expected, all 1,387 mecA-positive strains had penicillin MICs in the resistant range (Ն0.5 g/ml; 80% at Ͼ16 g/ml). There were 448 isolates (14.5% of all isolates, 26.4% of MSSA isolates) with a susceptible penicillin MIC of Յ0.12 g/ml. Thirtyone of the 448 isolates (6.9%) were blaZ positive (Table 1) and represented 32.1% of 53 isolates with a penicillin MIC of 0.12 g/ml and 3.8% of 370 isolates with a penicillin MIC of 0.06 g/ ml. None of the 25 isolates with a penicillin MIC of Յ0.03 g/ml contained blaZ.
Phenotypic ␤-lactamase screening test results for the 31 blaZpositive isolates are shown in Table 2 . One blaZ PCR-negative isolate (penicillin MIC, 0.12 g/ml) was positive by both phenotypic tests. The sensitivity and specificity of penicillin zone edge testing were 64.5% and 99.8%, respectively. The sensitivity and (9) . A larger Australian evaluation analyzing 157 isolates that appeared penicillin susceptible by agar dilution (38 were blaZ positive) noted 89% sensitivity and 100% specificity for the CLSI zone edge test (10) . The EUCAST zone edge test incorporating a lower-concentration (1-U) penicillin disk provided 100% sensitivity and specificity for penicillinase detection in the Australian study (10) . Lack of a CLSI quality control range and limited availability of the 1-U penicillin disk hinder further investigation of the EUCAST zone edge test. A U.S. study evaluating 105 isolates that appeared penicillin susceptible by disk diffusion found 10 (9.5%) to possess blaZ and noted variability among four readers of the CLSI penicillin zone edge test (with only 60% of those 10 strains having a sharp edge reported by all readers) (11) . The distribution of ␤-lactamase types detected in the present study among blaZ-positive isolates with a penicillin MIC of Յ0.12 g/ml was 26% A, 13% B, and 52% C. (Three isolates did not correspond to a known type [NT] .) The distribution was similar for isolates with higher penicillin MICs (Table 3) . A 2009 study analyzing 98 MSSA isolates reported no blaZ for 13%, type A ␤-lactamase for 26%, type B for 15%, and type C for 46% (8) . A South Korean study found type A blaZ in 17%, type B in 20%, type C in 53%, and type D in 1% of 220 MSSA isolates (12) . Cefazolin failures have been reported for MSSA infections caused by type A blaZ isolate demonstrating an inoculum effect (8) , but other retrospective studies have only found treatment success (12) . Prospective studies are needed to determine if screening MSSA isolates for a cefazolin inoculum effect has clinical utility.
A correlation of penicillin zone edge test performance with blaZ type was not apparent in the present study. The 11 isolates not detected by the zone edge method represented all of the blaZ types (37% of the 8 type A, 25% of the 4 type B, 38% of the 16 type C, and 33% of the 3 nontypeable [NT] isolates).
In conclusion, the CLSI penicillin zone edge method detected penicillinase production among 45% more blaZ-positive S. aureus isolates than nitrocefin-based testing. The failure of the CLSI zone edge test to detect 35% of blaZ-positive isolates is concerning. This study indicates that in the United States, 13.5% of S. aureus isolates (24.6% of MSSA isolates) are penicillin susceptible based on negative blaZ testing. Many labs do not routinely test for penicillin susceptibility (13, 14) . Although higher mortality has been reported for cefuroxime therapy of penicillin-susceptible MSSA bacteremia (15), superiority of penicillin over penicillinase-stable agents (e.g., dicloxacillin, nafcillin, and oxacillin) has not been proven. The limitations of phenotypic testing should be relayed to clinicians who request assessment of penicillin susceptibility. Molecular testing for blaZ is recommended before relying on penicillin for therapy of complicated MSSA infections.
(This work was presented in part at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 7 September 2014 [16] .)
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